Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
about
Update on the treatment of type 2 diabetes mellitusSex differences in type 2 diabetes: focus on disease course and outcomesMultiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptinManaging diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptinEfficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysisConsensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.A review of the efficacy and safety of oral antidiabetic drugsPharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.DPP-4 inhibitors: focus on safety.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.Ethnic Difference in the Pharmacodynamics-efficacy Relationship of Dipeptidyl Peptidase-4 Inhibitors Between Japanese and non-Japanese Patients: A Systematic Review.Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction.Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
P2860
Q28073342-9C0B38E7-6088-4405-9BAB-C93174233467Q34229975-A51F90C2-5765-4D53-AC6E-78983B031CA6Q34353892-C7899F68-E0D6-4511-95C3-525F146C440BQ34726395-AA205E55-5A38-4B74-8ABF-D5C1C2B6B818Q36706802-93833BA8-E9C1-4293-A264-20AD0317B20DQ36805122-66CC2AC3-08D2-4BFD-9939-84847041C838Q37176045-C615AA8F-EC15-4BF8-A436-DA73A80356E3Q37721962-47124B2F-8063-45D3-881D-800ED0032B18Q38067491-943517F7-8C86-462F-92F2-A4F4488532E3Q38086611-1F928FF9-A400-492C-9560-A53199EDBBC1Q38113092-FACE1521-18C1-47B1-B20E-EBD90AF477F8Q38199526-5DF9E9CE-6F62-4134-8395-EAF1E32E2D74Q38200670-C13E52EE-3073-4EF4-9807-CA540D5E77ABQ38205588-8A28C1BE-BC0B-435F-A7A1-B584ED292101Q38212472-224DD7DE-283E-4160-B822-6D915E65EF29Q38236774-A795F1DE-998B-40A0-AAE3-973845CFEEB4Q38261573-5B9C452D-69F8-4DD9-A0C0-CD2B8F26A0B6Q38285608-F5E36634-F1C1-450F-831D-5F1748DC1AA9Q38541323-8B2E8CA0-FA95-4E2B-BA17-780BE73C3038Q38546981-69AB9F9A-FB97-4C93-9100-7570AB6D28AEQ38828606-6D4524ED-EFB2-4A22-84E5-A34ACCF9512AQ38853658-F29B9208-FC38-4A6E-86BD-9C6DC67777A0Q41497267-A4ECBC15-5D08-4D72-975E-767F33D7F7D1Q42253478-D3039182-81EF-4530-B0BF-380D184B37B6Q46304493-FB51B419-E261-4912-BB62-C5528286C5F9Q47173429-DEFD844C-4C18-4942-A0A3-996A028366ED
P2860
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@en
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@nl
type
label
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@en
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@nl
prefLabel
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@en
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@nl
P2860
P1476
Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
@en
P2093
Yan-Ling He
P2860
P304
P356
10.2165/11598080-000000000-00000
P577
2012-03-01T00:00:00Z
P6179
1037013412